CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The LCAOS project is developing a novel diagnostic tool, the NaNose, to detect lung cancer and assess future risk using volatile biomarkers. This non-invasive device utilizes advanced nanotechnology and artificial intelligence to provide rapid, cost-effective screening.
The LCAOS project will develop and test a new diagnostic tool, able to detect:(i) the presence of lung cancer (LC), and(ii) an increased risk of a patient developing LC in the future.Diagnostic tests currently available are unsuitable for widespread screening because they are costly, occasionally miss tumours, are not time-efficient, nor free of complications.LCAOS will overcome these problems by using an approach based on volatile biomarkers emitted from cell membranes.
A multidisciplinary effo…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Austria, Innsbruck
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
United Kingdom, Liverpool
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Israel, Tel Aviv
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
